New Study Reveals Nevisense as a Promising Tool for Early Prediction of Atopic Dermatitis in Infants

In an exciting development for pediatric dermatology, SciBase Holding AB, a leading innovator in AI-driven skin health solutions, has announced the publication of a compelling study validating the effectiveness of its Nevisense technology in predicting atopic dermatitis (AD) in infants. This research, which recently appeared in the peer-reviewed journal Allergy, establishes that Nevisense measurements can accurately identify newborns who are likely to develop AD, a condition affecting 15-20% of children globally.

The study was conducted by researchers from the Icahn School of Medicine at Mount Sinai, who monitored the skin barrier health of infants shortly after birth using Nevisense technology. By analyzing the electrical impedance spectroscopy (EIS) measurements, the scientists were able to track skin barrier integrity during the first days of life. The findings revealed a significant correlation: infants destined to develop atopic dermatitis within their first year exhibited markedly higher EIS scores—indicative of compromised skin barriers—compared to their healthy peers.

This breakthrough could revolutionize the approach to atopic dermatitis, which often represents the initial phase of the so-called